Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, as a Single Agent or With Irinotecan, Irinotecan Plus Temozolomide, or With Cyclophosphamide Plus Topotecan in Pediatric Patients With Refractory Malignancies.

NCT04239092 is registered in ClinicalTrials.gov with Actuate Therapeutics Inc. as lead sponsor.

NCT NCT04239092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04239092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, as a Single Agent or With Irinotecan, Irinotecan Plus Temozolomide, or With Cyclophosphamide Plus Topotecan in Pediatric Patients With Refractory Malignancies.
Lead sponsor
Actuate Therapeutics Inc.
Phase
Phase 1
Overall status
Terminated
Start date
June 5, 2020
Completion date
July 7, 2025
Enrollment
40 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

cancer pediatric, diffuse intrinsic pontine glioma, neuroblastoma, neuroblastoma recurrent, pediatric brain tumor, pediatric cancer, pediatric lymphoma, pediatric meningioma, refractory cancer, refractory neoplasm, refractory tumor